Not yet recruitingInterventionalPhase 1Last updated Aug 7, 2026

Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function

A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Pharmacokinetics of Casdatifan (AB521) in Participants With Moderate Hepatic Impairment Compared to Healthy Matched Participants

Overview

ClinicalTrials.gov ID: NCT07751250
Lead Sponsor: Arcus Biosciences, Inc.INDUSTRY
Brief Summary: The purpose of the study is to compare the single dose PK of casdatifan between participants with moderate hepatic impairment (HI) and healthy matched control participants with normal hepatic function.
Study Type: Interventional

Status

Overall Status: Not yet recruiting
Start Date: Aug 2026Estimated
Primary Completion Date: May 2027Estimated
Completion Date: May 2027Estimated

Study Record Dates

First Submitted: Aug 3, 2026
First Submitted that Met QC Criteria: Aug 3, 2026
First Posted: Aug 7, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 3, 2026
Last Update Posted: Aug 7, 2026Actual
Last Verified: Aug 2026

NCT03309202Completed

Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment

NCT01571388Completed

A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment

NCT03626415Completed

A Hepatic Impairment Study for PF-04965842.

NCT04604496Completed

STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT

NCT07343960Recruiting

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

NCT07546760Recruiting

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234